Mounjaro®
Starting from £179.99/mo
Start journey Learn morePeople researching a semaglutide bodybuilding dosage are usually asking one of two things: whether the medicine can help them cut body fat while preserving muscle, or whether there is a separate dosing approach for athletic use. The honest answer is that semaglutide has no licensed bodybuilding dose and no clinical evidence base for that purpose. In the UK, semaglutide sold as Wegovy is a prescription-only medicine licensed specifically for weight management alongside a reduced-calorie diet and increased physical activity, reviewed individually by a prescriber before every prescription is written. Dose decisions belong to that prescriber, shaped by your health history and how your body responds during treatment, not by fitness goals alone. If you are considering it for body-composition purposes, understanding what the medicine actually does and how dosing works in practice will save you time and keep you safe.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Not in any licensed or clinically studied sense. The bodybuilding community has taken an interest in semaglutide because GLP-1 medicines do produce meaningful reductions in body weight, and some people assume a lower "performance dose" might trim fat without touching muscle. That assumption is understandable, but it is not how the medicine works or how it is prescribed.
Wegovy's titration schedule begins at 0.25 mg once weekly, moving through 0.5 mg, 1.0 mg and 1.7 mg before reaching the 2.4 mg maintenance dose, with roughly four weeks at each level. The 2.4 mg strength is where the main clinical evidence sits: the STEP 1 trial, published in the New England Journal of Medicine, found an average body-weight reduction of around 15% over 68 weeks at that dose alongside lifestyle changes. You can read a full breakdown of how the schedule progresses on the semaglutide dosage guide.
There are no published phase 3 trials testing semaglutide in athletes, recreational bodybuilders, or healthy people at sub-maintenance doses for body-composition purposes. The lower doses in the titration ladder exist to reduce gastrointestinal side effects while your body adjusts; they are not a therapeutic plateau to stay at indefinitely. A prescriber assessing you for Wegovy will set the pace of titration based on tolerability and response, not on a target physique.
Here is a misconception worth setting down gently: semaglutide does not selectively burn fat while leaving muscle alone. It reduces appetite, which leads to a calorie deficit, which causes weight loss. The composition of that weight loss (how much is fat and how much is lean tissue) depends on factors that are not controlled by the medicine itself: protein intake, training stimulus, sleep, and the size of the deficit.
Research into GLP-1 medicines and muscle mass is ongoing. Early analyses suggest that a meaningful proportion of weight lost on semaglutide can come from lean mass, particularly when protein intake is low and resistance exercise is absent. This is not unique to semaglutide; it applies to any significant calorie deficit. For someone who trains regularly, the practical implication is that adequate dietary protein and continued resistance work become more important during treatment, not less. The NHS patient information page for semaglutide covers the medicine's mechanism and common effects in plain terms worth reading.
People sometimes search for a specific semaglutide bodybuilding dose hoping that a lower amount might avoid these muscle effects. Clinical evidence does not support that approach. The dose-response relationship for weight loss also means lower doses generally produce less weight loss — and, in the absence of licensed evidence for sub-therapeutic use in healthy people, a prescriber would have no clinical basis for writing such a prescription.
Because this is a prescription-only medicine, eligibility is assessed individually. The licensed criteria for Wegovy cover adults with a BMI of 30 or above, or a BMI of 27 or above where at least one weight-related condition is present, such as high blood pressure, raised cholesterol, type 2 diabetes, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. If you are within those parameters and have a clinical reason for treatment, a prescriber can assess whether semaglutide is appropriate for you.
What matters is that a prescriber reviews your full picture: current medicines, medical history, and goals that are medically relevant. An interest in body composition alone, without a qualifying health condition or BMI, does not meet the licensed criteria. The Wegovy doses page explains the progression in more detail, and if you want to understand where the upper end of the licensed schedule sits, the maximum dosage of semaglutide page covers exactly that.
For context on cost, the Wegovy cost page sets out what private treatment typically involves, including what a legitimate price should cover. Treatment through a regulated online pharmacy means your prescriber sees your answers the same day (a real clinician, not a form processor) and repeats are reviewed clinically each time, not auto-renewed. If you meet the licensed criteria and want to explore whether semaglutide is right for you, our team is available to help.
If you do meet the eligibility criteria and are considering semaglutide, a few questions are genuinely worth raising at consultation. How should protein targets change during treatment? Is your training load likely to affect how quickly the medicine is titrated? What signs of muscle loss should prompt a conversation? These are medical questions with individual answers, which is exactly the kind of ground that a clinically trained prescriber is best placed to cover with you.
The slower the titration, the better most people tolerate the gastrointestinal effects of semaglutide. Starting low and moving up steadily is not a shortcut around the medicine's mechanism; it is built into the dosing schedule for good physiological reasons. If the initial steps feel unfamiliar, the smallest Wegovy dose page explains what to expect at the start of treatment, and the semaglutide dosage increase page covers what happens when titration moves forward. Both are worth reading before your first consultation. If you have additional questions first, the FAQs page covers many common queries about starting treatment.
Semaglutide is a carefully studied medicine with a defined place in weight management care. Used within that framework, with good nutritional habits and structured exercise, many people find it supports meaningful progress. Used outside it, without a clinical basis, the risks are uncharted and the prescriptions simply are not available through any legitimate UK pharmacy. Speak to our prescribers if you want to understand whether treatment is suitable for you.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.